A wide variety of mechanisms of anti-rheumatic action have been proposed for antimalarial agents. The molecular actions of chloroquine have been most thoroughly studied in vitro and in vivo, but it is likely that hydroxychloroquine works by a similar mechanism. Both agents are weak diprotic bases that can pass through the lipid cell membrane and preferentially concentrate in acidic cyto-plasmic vesicles. The resulting slight elevation of pH within these vesicles in macrophages or other antigen-presenting cells may influence the immune response to autoantigens. We hypothesize that anti-malarial agents influence the association of autoantigenic peptides with class II MHC molecules in the compartment for peptide loading and/or the subsequent processing and transport of the peptide-MHC complex to the cell membrane. This model of anti-malarial action provides a method to test additional drugs for their ability to modulate the immune response.
WallaceD.Anti-malarial drugs.Rheum Dis Clin North Am1994; 20: 243–263.
2.
UnanueE.Antigen-presenting function of the macrophage.Annu Rev. Immunol1984; 2: 395.
3.
DuboisEL: Anti-malarials in the management of discoid and systemic lupus erythematosus.Semin Arthritis Rheum1978; 8: 33–51.
4.
TeytonL. Invariant chain distinguishes between the exogenous and endogenous antigen presentation pathways.Nature1990; 348: 39–44.
5.
PetersonM, MillerJ.Invariant chain influences the immunological recognition of MHC class II molecules.Nature1990; 345: 172–174.
6.
ZieglerHK, UnanueER.Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells.Proc Natl Acad Sci USA1982; 79: 175.
7.
OhkumaS, PooleB.Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents.Proc Natl Acad Sci USA1978; 75: 3327–2221.
8.
KoevarySB, BlombergM.Prevention of diabetes in BB/Wor rats by intra-thymic islet injection.J Clin Invest1992; 89: 512–516.
9.
KaufmanDL. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes.Nature1993; 366: 69–72.
10.
TischR. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice.Nature1993; 366: 72–75.
11.
HeroldKC, MontagAG, BuckinghamE.Induction of tolerance to autoimmune diabetes with islet antigens.J Exp Med1992; 176: 1107–1114.
12.
VauxDL.Toward an understanding of the molecular mechanisms of physiological cell death.Proc Natl Acad Sci USA1993; 90: 786–789.
13.
MalnatiMS. Processing pathways for presentation of cytosolic antigen to MHC class II-restricted T cells.Nature1992; 357: 702–706.
14.
LotteauV. Intracellular transport of class II MCH molecules directed by invariant chain.Nature1990; 348: 600–606.
15.
LehmannPV. Determinant spreading and the dynamics of the autoimmune T-cell repertoire.Immunol Today1993; 14: 203–208.
16.
TeytonL, PetersonPA.Assembly and transport of MHC class II molecules.New Biol1992; 4: 441–447.
17.
MamulaMJ, LinR-H, JanewayCAJr., HardinJA.Breaking T cell tolerance with foreign and self co-immunogens. A study of autoimmune B and T cell epitopes of cytochrome c.J Immunol1992; 149: 789–795.
18.
GammonG, SercarzEE, BenichouG.The dominant self and the cryptic self: Shaping the autoreactive T-cell repertoire.Immunol Today1991; 12: 193–195.
19.
KarlssonL. Reconstitution of an operational MHC class II compartment in nonantigen-presented cells.Science1994; 226: 1569–1573.
20.
SchmidSL, JacksonMR.Making class II presentable.Nature1994; 369: 103–105.
21.
RochePA, CresswellP.Proteolysis of the class II-associated invariant chain generates a peptide binding site in intracellular HLA-DR molecules.Proc Natl Acad Sci USA1991; 88: 3150–3154.
22.
BlumJS, CresswellP.Role for intracellular proteases in the processing and transport of class II HLA antigens.Proc Natl Acad Sci USA1988; 85: 3975–3979.
23.
JensenPE.Regulation of antigen presentation by acidic pH.J Exp Med1990; 171: 1779–1784.
24.
CainCC, SipeDM, MurphyRF.Regulation of endocytic pH by the Na+, K+-ATPase in living cells.Proc Natl Acad Sci USA1989; 86: 544–548.
25.
TulpA. Isolation and characterization of the intracellular MHC class II compartment.Nature1994; 369: 120–123.
26.
AmigorenaS, DrakeJR, WebsterP, MellmanI.Transient accumulation of new class II MHC molecules in a novel endocytic compartment in B lymphocytes.Nature1994; 369: 113–116.
27.
HomewoodCA, WarhurstDC, PetersW, BaggaleyVC.Lysosomes, pH and the anti-malarial action of chloroquine.Nature1972; 235: 50–52.
28.
HERA.A randomized trial of hydroxychloroquine in early rheumatoid arthritis: The HERA study.Am J Med1995; 98: 156.
29.
NowellJ, QuarantaV.Chloroquine affects biosynthesis of Ia molecules by inhibiting dissociation of invariant (gamma) chains from α-β dimers in B cells.J Exp Med1985; 162: 1371–1376.
30.
JanewayCAJr., BottomlyK: Signals and signs for lymphocyte responses.Cell1994; 76: 275–285.
31.
FoxRI, KangHI.Mechanism of action of hydroxychloroquine as an antirheumatic drug.Semin Arthritis Rheum1993; 23: 82–91.
32.
HamiltonE, ScottJ.Hydroxychloroquine in treatment of rheumatoid arthritis.Arthritis Rheum1962; 5: 502.
33.
ZiffM, EssermanP, McKwanC.Observations on the course and treatment of systemic lupus erythematosus.Arthritis Rheum1958; 1: 332.
34.
BykerkV. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus.N Engl J Med1991; 324: 150.
35.
CohenS, YieldingK.Inhibition of DNA and RNA polymerase reactions by chloroquine.Proc Natl Acad Sci USA1965; 54: 521–527.
36.
FilippovA. Ca + + antagonistic properties of phospholipase A2 inhibitors, mepacrine and chloroquine.Gen Physiol Biophys1989; 8: 113–118.
37.
MatsuzawaY, HestetlerKY.Inhibition of lysosomal phospholipase A and phospholipase C by chloroquine and 4,4′bis (diethylaminoethoxy) alpha, beta-diethylane,J Biol Chem1980; 255: 5190–5194.
38.
HurstN. Chloroquine and hydroxychloroquine inhibit multiples sites in metabolic pathways leading to neutrophil superoxide release.J Rheumatol1988; 15: 23.
39.
SalmeronG, LipskyPE.Immunosuppressive potentials of antimalarials.Am J Med1983; 75(Suppl la): 19–24.
40.
PicotS. Chloroquine inhibits tumor necrosis factor production by human macrophages in vitro.J Infect Dis1991; 164: 830.
41.
NaimiuchiS. Quinacrine inhibits the primary but not secondary proliferative response of human cytotoxic T cells to allogeneic non-T-cell antigens.J Immunol1984; 123: 1456–1461.
